BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21463909)

  • 21. The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment.
    Alström U; Tydén H; Oldgren J; Siegbahn A; Ståhle E
    Thromb Res; 2007; 120(3):353-9. PubMed ID: 17137616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.
    Park DW; Ahn JM; Song HG; Lee JY; Kim WJ; Kang SJ; Yun SC; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Am Heart J; 2013 Jan; 165(1):34-42.e1. PubMed ID: 23237131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
    Spinler SA
    Pharmacotherapy; 2009 Jul; 29(7):812-21. PubMed ID: 19558255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    ; Mehta SR; Bassand JP; Chrolavicius S; Diaz R; Eikelboom JW; Fox KA; Granger CB; Jolly S; Joyner CD; Rupprecht HJ; Widimsky P; Afzal R; Pogue J; Yusuf S
    N Engl J Med; 2010 Sep; 363(10):930-42. PubMed ID: 20818903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
    Vavuranakis M; Latsios G; Aggelis D; Bosinakou I; Karambelas I; Tousoulis D; Toutouzas K; Stefanadis C
    Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
    Rubboli A; Halperin JL
    Thromb Haemost; 2008 Nov; 100(5):752-3. PubMed ID: 18989515
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
    Kirshner HS
    Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
    Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
    Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
    Roldán V; Marín F
    Thromb Haemost; 2008 Nov; 100(5):754-5. PubMed ID: 18989516
    [No Abstract]   [Full Text] [Related]  

  • 33. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
    Fox KA; Mehta SR; Peters R; Zhao F; Lakkis N; Gersh BJ; Yusuf S;
    Circulation; 2004 Sep; 110(10):1202-8. PubMed ID: 15313956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiplatelet therapy in acute coronary syndromes: the emergency physician's perspective.
    Pollack CV; Hollander JE
    J Emerg Med; 2008 Jul; 35(1):5-13. PubMed ID: 18359601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aprotinin reduces the antiplatelet effect of clopidogrel.
    Lindvall G; Sartipy U; Bjessmo S; Svenarud P; Lindvall B; van der Linden J
    Interact Cardiovasc Thorac Surg; 2009 Aug; 9(2):178-81. PubMed ID: 19477870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors].
    Rosa A; Canaple S
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1563-8. PubMed ID: 9092419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome.
    Ng FH; Wong SY; Lam KF; Chang CM; Lau YK; Chu WM; Wong BC
    Am J Gastroenterol; 2008 Apr; 103(4):865-71. PubMed ID: 18177451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
    Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential Interaction between clopidogrel and proton pump inhibitors.
    Howard PA; Vacek JL
    Am J Cardiovasc Drugs; 2009; 9(6):353-9. PubMed ID: 19929033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.